Literature DB >> 10666368

Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass.

P Dias1, B Chen, B Dilday, H Palmer, H Hosoi, S Singh, C Wu, X Li, J Thompson, D Parham, S Qualman, P Houghton.   

Abstract

Rhabdomyosarcomas are a heterogeneous group of tumors with respect to their molecular basis, degree of differentiation, histology, and clinical behavior. Because of the wide variation of tumor morphology, it is often difficult to distinguish between the distinct subtypes of rhabdomyosarcomas. By using cryosections of tumor specimens and immunohistochemistry, in the present study we show that strong expression of myogenin in rhabdomyosarcoma is associated with alveolar histology (P = <0.0001, Fisher's exact test). Although staining for myogenin was observed in 22 of 26 rhabdomyosarcomas, all alveolar rhabdomyosarcomas (nine of nine) showed high levels of staining for myogenin, as defined by the frequency and intensity of staining of the tumor cells. The staining pattern suggests that the tumor cells are clonally derived from myogenin-positive progenitor cells. In contrast, most embryonal rhabdomyosarcomas (13 of 15) were either negative or showed a low level of staining for myogenin. In these tumors a larger proportion of tumor cells were distinctly negative for myogenin. Six of seven alveolar rhabdomyosarcomas that strongly stained for myogenin were also positive for Pax3-7/Forkhead (FKHR) by polymerase chain reaction/reverse transcriptase-polymerase chain reaction. One of two embryonal rhabdomyosarcomas that strongly stained for myogenin was retrospectively found to be positive for Pax3/FKHR transcripts. Quantitative analysis for myogenin by Western blotting using a smaller subset of rhabdomyosarcomas revealed that in general there was a good correlation between immunohistochemical staining and Western blotting (P = 0.01, Pearson Correlation), although the former technique was more sensitive for detecting tumors with low levels of the protein. On average, alveolar rhabdomyosarcomas expressed at least threefold more myogenin than embryonal rhabdomyosarcomas. Our data show that staining for myogenin will be a simple, rapid, and accurate adjunct for distinguishing between alveolar and embryonal rhabdomyosarcomas. We propose that embryonal rhabdomyosarcomas result from an early block in myogenesis, before the expression of myogenin. In contrast, we propose that alveolar rhabdomyosarcomas either originate from a late block in myogenesis (after expression of myogenin) or that the pathological mechanisms involved in these neoplasms also induce strong expression of this protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666368      PMCID: PMC1850049          DOI: 10.1016/S0002-9440(10)64743-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  Rhabdomyosarcoma: a clinicopathological study and classification of 39 cases.

Authors:  R C HORN; H T ENTERLINE
Journal:  Cancer       Date:  1958 Jan-Feb       Impact factor: 6.860

2.  The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.

Authors:  S Scheidler; W J Fredericks; F J Rauscher; F G Barr; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

3.  Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis.

Authors:  C M Coffin; J Rulon; L Smith; C Bruggers; F V White
Journal:  Mod Pathol       Date:  1997-12       Impact factor: 7.842

4.  Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue.

Authors:  M Maroto; R Reshef; A E Münsterberg; S Koester; M Goulding; A B Lassar
Journal:  Cell       Date:  1997-04-04       Impact factor: 41.582

5.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

6.  Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development.

Authors:  P N Tonin; H Scrable; H Shimada; W K Cavenee
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

7.  Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas.

Authors:  B Chen; P Dias; J J Jenkins; V H Savell; D M Parham
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

8.  Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I.

Authors:  R B Raney; M Tefft; H M Maurer; A H Ragab; D M Hays; E H Soule; M A Foulkes; E A Gehan
Journal:  Cancer       Date:  1988-10-01       Impact factor: 6.860

9.  Pax3 inhibits myogenic differentiation of cultured myoblast cells.

Authors:  J A Epstein; P Lam; L Jepeal; R L Maas; D N Shapiro
Journal:  J Biol Chem       Date:  1995-05-19       Impact factor: 5.157

10.  Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD.

Authors:  S Tajbakhsh; D Rocancourt; G Cossu; M Buckingham
Journal:  Cell       Date:  1997-04-04       Impact factor: 41.582

View more
  42 in total

1.  Immunohistochemical detection of myogenin and p21 in methylcholanthrene-induced mouse rhabdomyosarcomas.

Authors:  Makoto Inoue; Haiyan Wu
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

Review 2.  Primary pulmonary rhabdomyosarcoma in an adult: a case report and review of the literature.

Authors:  Gui-yi Ji; Hui Mao
Journal:  J Zhejiang Univ Sci B       Date:  2013-09       Impact factor: 3.066

3.  Immunohistochemical quantification of the vitamin B12 transport protein (TCII), cell surface receptor (TCII-R) and Ki-67 in human tumor xenografts.

Authors:  Annette M Sysel; Victor E Valli; Ray B Nagle; Joseph A Bauer
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

4.  Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.

Authors:  L Krsková; M Mrhalová; D Sumerauer; R Kodet
Journal:  Virchows Arch       Date:  2005-12-20       Impact factor: 4.064

5.  Huge cranio-cerebral rhabdomyosarcoma in HIV-positive patient.

Authors:  Liverana Lauretti; Nicola Montano; Giovanna Paternoster; Eduardo Fernandez; Mariangela Novello; Libero Lauriola; Roberto Pallini
Journal:  J Neurooncol       Date:  2010-02-27       Impact factor: 4.130

6.  Clinical utility gene card for: Alveolar rhabdomyosarcoma.

Authors:  Zhongxin Yu; Anna Kelsey; Rita Alaggio; David Parham
Journal:  Eur J Hum Genet       Date:  2011-08-10       Impact factor: 4.246

7.  Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases.

Authors:  Thomas Mentzel; Cornelius Kuhnen
Journal:  Virchows Arch       Date:  2006-09-30       Impact factor: 4.064

8.  Head and Neck Rhabdomyosarcoma: Clinical and Pathologic Characterization of Seven Cases.

Authors:  Eleanor Chen; Robert Ricciotti; Neal Futran; Dolphine Oda
Journal:  Head Neck Pathol       Date:  2016-11-28

9.  Immunohistochemistry as an important tool in biomarkers detection and clinical practice.

Authors:  Leandro Luongo de Matos; Damila Cristina Trufelli; Maria Graciela Luongo de Matos; Maria Aparecida da Silva Pinhal
Journal:  Biomark Insights       Date:  2010-02-09

Review 10.  Rhabdomyoblastic Differentiation in Head and Neck Malignancies Other Than Rhabdomyosarcoma.

Authors:  Justin A Bishop; Lester D R Thompson; Antonio Cardesa; Leon Barnes; James S Lewis; Asterios Triantafyllou; Henrik Hellquist; Goran Stenman; Jennifer L Hunt; Michelle D Williams; Pieter J Slootweg; Kenneth O Devaney; Douglas R Gnepp; Bruce M Wenig; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck Pathol       Date:  2015-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.